Transcriptional regulation of organic anion transporting polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease

Takehiro Suzuki, Takafumi Toyohara, Yasutoshi Akiyama, Yoichi Takeuchi, Eikan Mishima, Chitose Suzuki, Sadayoshi Ito, Tomoyoshi Soga, Takaaki Abe

研究成果: Article

18 引用 (Scopus)

抄録

Uremic toxins accumulate in patients with chronic kidney diseases (CKDs) and cause further progression of renal damage and cardiovascular diseases. Recently, it was reported that some of the organic anion transporting polypeptides (OATPs) and the organic anion transporters (OATs) are involved in the renal elimination of uremic toxins. SLCO4C1 is the only OATP expressed at the basolateral side of proximal tubular cells in human kidney, and it mediates the excretion of uremic toxins. The overexpression of human SLCO4C1 in rat kidney promotes the renal excretion of uremic toxins and reduces hypertension, cardiomegaly, and renal inflammation in renal failure. Statins induce SLCO4C1 expression thorough transcriptional factor Aryl hydrocarbon receptor through binding of the xenobiotic responsive element at its promoter region. The administration of statin in a rat renal failure model facilitated the elimination of uremic toxins and mitigated organ damage. In addition, metabolomic analysis of rat renal failure models and patients with CKD by capillary electrophoresis-mass spectrometry is a useful method for identifying new uremic solutes and explores surrogate biomarkers for detecting the progression of early stage CKD.

元の言語English
ページ(範囲)3696-3707
ページ数12
ジャーナルJournal of Pharmaceutical Sciences
100
発行部数9
DOI
出版物ステータスPublished - 2011 9

Fingerprint

Chronic Renal Insufficiency
Renal Insufficiency
Anions
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Kidney
Peptides
Organic Anion Transporters
Aryl Hydrocarbon Receptors
Renal Hypertension
Metabolomics
Capillary Electrophoresis
Cardiomegaly
Xenobiotics
Genetic Promoter Regions
Mass Spectrometry
Cardiovascular Diseases
Therapeutics
Biomarkers
Inflammation
Renal Elimination

ASJC Scopus subject areas

  • Pharmaceutical Science

これを引用

Transcriptional regulation of organic anion transporting polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease. / Suzuki, Takehiro; Toyohara, Takafumi; Akiyama, Yasutoshi; Takeuchi, Yoichi; Mishima, Eikan; Suzuki, Chitose; Ito, Sadayoshi; Soga, Tomoyoshi; Abe, Takaaki.

:: Journal of Pharmaceutical Sciences, 巻 100, 番号 9, 09.2011, p. 3696-3707.

研究成果: Article

Suzuki, Takehiro ; Toyohara, Takafumi ; Akiyama, Yasutoshi ; Takeuchi, Yoichi ; Mishima, Eikan ; Suzuki, Chitose ; Ito, Sadayoshi ; Soga, Tomoyoshi ; Abe, Takaaki. / Transcriptional regulation of organic anion transporting polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease. :: Journal of Pharmaceutical Sciences. 2011 ; 巻 100, 番号 9. pp. 3696-3707.
@article{226b820b1a7843b6ab3ff9fe77abd009,
title = "Transcriptional regulation of organic anion transporting polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease",
abstract = "Uremic toxins accumulate in patients with chronic kidney diseases (CKDs) and cause further progression of renal damage and cardiovascular diseases. Recently, it was reported that some of the organic anion transporting polypeptides (OATPs) and the organic anion transporters (OATs) are involved in the renal elimination of uremic toxins. SLCO4C1 is the only OATP expressed at the basolateral side of proximal tubular cells in human kidney, and it mediates the excretion of uremic toxins. The overexpression of human SLCO4C1 in rat kidney promotes the renal excretion of uremic toxins and reduces hypertension, cardiomegaly, and renal inflammation in renal failure. Statins induce SLCO4C1 expression thorough transcriptional factor Aryl hydrocarbon receptor through binding of the xenobiotic responsive element at its promoter region. The administration of statin in a rat renal failure model facilitated the elimination of uremic toxins and mitigated organ damage. In addition, metabolomic analysis of rat renal failure models and patients with CKD by capillary electrophoresis-mass spectrometry is a useful method for identifying new uremic solutes and explores surrogate biomarkers for detecting the progression of early stage CKD.",
keywords = "ABC transporters, Capillary electrophoresis, Chronic kidney disease, Mass spectrometry, Membrane transport, Metabolome analysis, Organic anion transporter, Organic anion-transporting polypeptide transporters, Statin, Uremic toxin",
author = "Takehiro Suzuki and Takafumi Toyohara and Yasutoshi Akiyama and Yoichi Takeuchi and Eikan Mishima and Chitose Suzuki and Sadayoshi Ito and Tomoyoshi Soga and Takaaki Abe",
year = "2011",
month = "9",
doi = "10.1002/jps.22641",
language = "English",
volume = "100",
pages = "3696--3707",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Transcriptional regulation of organic anion transporting polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease

AU - Suzuki, Takehiro

AU - Toyohara, Takafumi

AU - Akiyama, Yasutoshi

AU - Takeuchi, Yoichi

AU - Mishima, Eikan

AU - Suzuki, Chitose

AU - Ito, Sadayoshi

AU - Soga, Tomoyoshi

AU - Abe, Takaaki

PY - 2011/9

Y1 - 2011/9

N2 - Uremic toxins accumulate in patients with chronic kidney diseases (CKDs) and cause further progression of renal damage and cardiovascular diseases. Recently, it was reported that some of the organic anion transporting polypeptides (OATPs) and the organic anion transporters (OATs) are involved in the renal elimination of uremic toxins. SLCO4C1 is the only OATP expressed at the basolateral side of proximal tubular cells in human kidney, and it mediates the excretion of uremic toxins. The overexpression of human SLCO4C1 in rat kidney promotes the renal excretion of uremic toxins and reduces hypertension, cardiomegaly, and renal inflammation in renal failure. Statins induce SLCO4C1 expression thorough transcriptional factor Aryl hydrocarbon receptor through binding of the xenobiotic responsive element at its promoter region. The administration of statin in a rat renal failure model facilitated the elimination of uremic toxins and mitigated organ damage. In addition, metabolomic analysis of rat renal failure models and patients with CKD by capillary electrophoresis-mass spectrometry is a useful method for identifying new uremic solutes and explores surrogate biomarkers for detecting the progression of early stage CKD.

AB - Uremic toxins accumulate in patients with chronic kidney diseases (CKDs) and cause further progression of renal damage and cardiovascular diseases. Recently, it was reported that some of the organic anion transporting polypeptides (OATPs) and the organic anion transporters (OATs) are involved in the renal elimination of uremic toxins. SLCO4C1 is the only OATP expressed at the basolateral side of proximal tubular cells in human kidney, and it mediates the excretion of uremic toxins. The overexpression of human SLCO4C1 in rat kidney promotes the renal excretion of uremic toxins and reduces hypertension, cardiomegaly, and renal inflammation in renal failure. Statins induce SLCO4C1 expression thorough transcriptional factor Aryl hydrocarbon receptor through binding of the xenobiotic responsive element at its promoter region. The administration of statin in a rat renal failure model facilitated the elimination of uremic toxins and mitigated organ damage. In addition, metabolomic analysis of rat renal failure models and patients with CKD by capillary electrophoresis-mass spectrometry is a useful method for identifying new uremic solutes and explores surrogate biomarkers for detecting the progression of early stage CKD.

KW - ABC transporters

KW - Capillary electrophoresis

KW - Chronic kidney disease

KW - Mass spectrometry

KW - Membrane transport

KW - Metabolome analysis

KW - Organic anion transporter

KW - Organic anion-transporting polypeptide transporters

KW - Statin

KW - Uremic toxin

UR - http://www.scopus.com/inward/record.url?scp=79960134351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960134351&partnerID=8YFLogxK

U2 - 10.1002/jps.22641

DO - 10.1002/jps.22641

M3 - Article

C2 - 21656517

AN - SCOPUS:79960134351

VL - 100

SP - 3696

EP - 3707

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 9

ER -